Alan A. Musso's most recent trade in Fulcrum Therapeutics Inc was a trade of 285,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 24, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Fulcrum Therapeutics Inc | Alan A. Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 285,000 | 285,000 | - | - | Stock Option (right to buy) | |
Rein Therapeutics Inc. | Alan A. Musso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2024 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
Rein Therapeutics Inc. | Alan A. Musso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2024 | 2,725 | 2,725 | - | - | Stock Option (right to buy) | |
Fulcrum Therapeutics Inc | A. Alan Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
Fulcrum Therapeutics Inc | Alan Musso A. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 61,822 | 61,822 | - | - | Stock Option (right to buy) | |
Fulcrum Therapeutics Inc | Alan A. Musso | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2023 | 432,800 | 432,800 | - | - | Stock Option (right to buy) |